Copyright
©The Author(s) 2015.
World J Clin Oncol. Oct 10, 2015; 6(5): 166-173
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.166
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.166
Table 1 Baseline characteristics
| Characteristic | Placebo(n = 8) | Selenium(n = 10) | P value | |
| Median age | 55.5 | 59.5 | 0.700 | |
| Male sex | 7 | 10 | 0.165 | |
| Race | White | 4 | 8 | 0.180 |
| Other | 4 | 2 | ||
| Best response | CR | 7 | 6 | 0.196 |
| Not evaluable | 1 | 4 | ||
| T stage | 1 | 3 | 0 | 0.063 |
| 2 | 2 | 5 | ||
| 3 | 0 | 3 | ||
| 4 | 3 | 1 | ||
| X | 0 | 1 | ||
| N stage | 1 | 0 | 1 | 0.103 |
| 2 | 6 | 8 | ||
| 3 | 1 | 1 | ||
| X | 1 | 0 | ||
| M stage | 0 | 5 | 10 | 0.105 |
| X | 3 | 0 | ||
| Stage group | IVA | 7 | 8 | 0.108 |
| IVB | 1 | 1 | ||
| Unkn | 0 | 1 | ||
- Citation: Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB. Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015; 6(5): 166-173
- URL: https://www.wjgnet.com/2218-4333/full/v6/i5/166.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i5.166